The use of novel immunotherapeutic agents, such as nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), and atezolizumab (anti PD-L1), has led to the improved overall survival of NSCLC patients compared to treatment with docetaxel [16,21,22]. Here, CD274 is linked to non-small cell lung carcinoma.